Home The Word Brain My Amedeo FAQ Privacy About   


Hanzi Hunter — ultra-fast Hanzi study

All 1,152 characters from the aioLingua manual

AbstractAboutThe 20 audio files

← aioLingua Chinese Online

← Chinese aioLingua PDF


  Diabetes

  Free Subscription


Articles published in J Am Soc Nephrol

Retrieve available abstracts of 31 articles:
HTML format



Single Articles


    November 2025
  1. MATSOUKAS C, Tomic TT, Tonelius P, Nunez-Duran E, et al
    Streamlining the Histopathological Workflow in Diabetic Kidney Disease with Artificial Intelligence.
    J Am Soc Nephrol. 2025 Nov 12. doi: 10.1681/ASN.0000000923.
    PubMed     Abstract available


    October 2025
  2. SRIDHAR VS, Odutayo A, Davies MJ, Cherney DZI, et al
    Authors' Reply: Further Considerations on the Clinical Evaluation of Sotagliflozin in Type 1 Diabetes with CKD.
    J Am Soc Nephrol. 2025 Oct 10. doi: 10.1681/ASN.0000000868.
    PubMed    


  3. WANG R, Xie J, Wang M
    Further Considerations on the Clinical Evaluation of Sotagliflozin in Type 1 Diabetes with CKD.
    J Am Soc Nephrol. 2025 Oct 10. doi: 10.1681/ASN.0000000867.
    PubMed    


    September 2025
  4. RHEE CM, Allon M, Mehrotra R
    Commemorating the National Institute of Diabetes and Digestive and Kidney Diseases' Advances in Kidney Health: 75 Years of Discovery and Impact.
    J Am Soc Nephrol. 2025 Sep 30. doi: 10.1681/ASN.0000000898.
    PubMed     Abstract available


  5. FERREIRA JP, Mendonca L, Marques P, Neves JS, et al
    Albuminuria Is the Key Driver of Kidney Benefit with Aldosterone Receptor Antagonists in Type 2 Diabetes.
    J Am Soc Nephrol. 2025 Sep 2. doi: 10.1681/ASN.0000000877.
    PubMed    


    June 2025
  6. HANNEDOUCHE T
    Acetazolamide and Glomerular Hyperfiltration in Type 1 Diabetes: Additional Insights from Early Clinical Research.
    J Am Soc Nephrol. 2025 Jun 23. doi: 10.1681/ASN.0000000780.
    PubMed    


  7. HEERSPINK HJL, Friedman AN, Bjornstad P, van Raalte DH, et al
    Kidney Parameters with Tirzepatide in Obesity with or without Type 2 Diabetes.
    J Am Soc Nephrol. 2025 Jun 13. doi: 10.1681/ASN.0000000764.
    PubMed     Abstract available


    May 2025
  8. KRISHNA PATEL HA, Wang J, Zinn CJ, Learmonth M, et al
    Fortifying the Diabetic Kidney Disease Treatment Armamentarium: Multitarget Senotherapeutic and Regenerative Strategies.
    J Am Soc Nephrol. 2025 May 7. doi: 10.1681/ASN.0000000754.
    PubMed    


  9. RASHID AM, Khan MS, Cherney DZI, Mehta A, et al
    Rapid and Simultaneous Initiation of Guideline-Directed Kidney Therapies in Patients with CKD and Type 2 Diabetes.
    J Am Soc Nephrol. 2025 May 6. doi: 10.1681/ASN.0000000752.
    PubMed     Abstract available


  10. COLE JB, Dahlstrom EH, Fermin D, Gupta Y, et al
    Genome-Wide Association Study of Quantitative Kidney Function in 52,531 Individuals with Diabetes Identifies Five Diabetes-Specific Loci.
    J Am Soc Nephrol. 2025 May 5. doi: 10.1681/ASN.0000000718.
    PubMed     Abstract available


    March 2025
  11. LI XQ, Zhang JX, Li L, Wu QY, et al
    Deficiency of GADD45alpha-R-Loop Pathway and Kidney Injury in Diabetic Nephropathy.
    J Am Soc Nephrol. 2025 Mar 18. doi: 10.1681/ASN.0000000681.
    PubMed     Abstract available


  12. ABE M, Niioka H, Matsumoto A, Katsuma Y, et al
    Self-Supervised Learning for Feature Extraction from Glomerular Images and Disease Classification with Minimal Annotations.
    J Am Soc Nephrol. 2025;36:471-486.
    PubMed     Abstract available


    February 2025
  13. SRIDHAR VS, Kugathasan L, Lovblom LE, Huajing N, et al
    Indexing GFR Using Extracellular Volume versus Body Surface Area in a Population with Type 1 Diabetes and DKD.
    J Am Soc Nephrol. 2025 Feb 21. doi: 10.1681/ASN.0000000668.
    PubMed    


  14. LI W, Zhang Z, Peng Z, Hu H, et al
    PIEZO1-Mediated Calcium Signaling and Podocyte Injury in Diabetic Kidney Disease.
    J Am Soc Nephrol. 2025 Feb 11. doi: 10.1681/ASN.0000000634.
    PubMed     Abstract available


    January 2025
  15. COCA SG, Nadkarni GN
    KidneyintelX.dkd: An Innovation in Precision Medicine for Diabetic Kidney Disease.
    J Am Soc Nephrol. 2025 Jan 30. doi: 10.1681/ASN.0000000644.
    PubMed    


  16. BORG R, Cherney DZ
    Glomerular Hyperfiltration and Tubuloglomerular Feedback in Diabetic Kidney Disease: Physiological Insights and Potential Clinical Translation.
    J Am Soc Nephrol. 2025 Jan 22. doi: 10.1681/ASN.0000000615.
    PubMed    


  17. TANG M, Morieri ML, Kalim S, Doria A, et al
    Combination Therapy with SGLT2 Inhibitors and GLP-1 Receptor Agonists for Diabetic Kidney Disease.
    J Am Soc Nephrol. 2025 Jan 7. doi: 10.1681/ASN.0000000620.
    PubMed    


    November 2024
  18. MEHTA SS, Surapaneni AL, Pandit K, Xu Y, et al
    Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter 2 Inhibitor Prescriptions in Type 2 Diabetes by Kidney and Cardiovascular Disease.
    J Am Soc Nephrol. 2024 Nov 27. doi: 10.1681/ASN.0000000585.
    PubMed    


  19. SRIDHAR VS, Odutayo A, Garg S, Danne T, et al
    Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes and CKD.
    J Am Soc Nephrol. 2024 Nov 1. doi: 10.1681/ASN.0000000540.
    PubMed     Abstract available


    October 2024
  20. MIN L, Chen Y, Liu R, Li Z, et al
    Targeting KLF2 as a Novel Therapy for Glomerular Endothelial Cell Injury in Diabetic Kidney Disease.
    J Am Soc Nephrol. 2024 Oct 9. doi: 10.1681/ASN.0000000000000498.
    PubMed     Abstract available


  21. GINSBERG C, Seegmiller JC, Vallon V, SeungMi Jin S, et al
    Acetazolamide Therapy and Kidney Function in Persons with Non-albuminuric Diabetes Mellitus Type 1.
    J Am Soc Nephrol. 2024 Oct 8. doi: 10.1681/ASN.0000000515.
    PubMed     Abstract available


  22. BAKKER WM, Gansevoort RT, Yang C, Chertow GM, et al
    Sodium-Glucose Cotransporter 2 Inhibitors in Older Patients with CKD.
    J Am Soc Nephrol. 2024;35:1446-1449.
    PubMed    


    September 2024
  23. TOUYZ RM
    Learning from Negative Trials for Diabetic Kidney Disease.
    J Am Soc Nephrol. 2024 Sep 26. doi: 10.1681/ASN.0000000511.
    PubMed    


    August 2024
  24. COOPER M, Cherney DZI, Greene TH, Heerspink HJL, et al
    Vascular Endothelial Growth Factor (VEGF)-B Blockade with CSL346 in Diabetic Kidney Disease: A Phase 2A Randomized Controlled Trial.
    J Am Soc Nephrol. 2024 Aug 16. doi: 10.1681/ASN.0000000000000438.
    PubMed     Abstract available


    July 2024
  25. THOMAS RL, Rifkin DE
    Renal Reinforcements: Slowing Diabetic Kidney Disease with Multiple New Agents.
    J Am Soc Nephrol. 2024 Jul 30. doi: 10.1681/ASN.0000000000000458.
    PubMed    


  26. HEERSPINK HJL, Perkovic V, Tuttle KR, Pergola PE, et al
    Selonsertib in Patients with Diabetic Kidney Disease: A Phase 2b Randomized Active Run-In Clinical Trial.
    J Am Soc Nephrol. 2024 Jul 17. doi: 10.1681/ASN.0000000000000444.
    PubMed     Abstract available


    May 2024
  27. VELICKOVIC D, Shapiro JP, Parikh SV, Rovin B, et al
    Protein N-glycans in Healthy and Sclerotic Glomeruli in Diabetic Kidney Disease.
    J Am Soc Nephrol. 2024 May 21. doi: 10.1681/ASN.0000000000000393.
    PubMed     Abstract available


  28. DOKE T, Bjornstad P
    Endothelial-Mesenchymal Transition Switch and Diabetic Kidney Disease.
    J Am Soc Nephrol. 2024 May 3. doi: 10.1681/ASN.0000000000000364.
    PubMed    


    April 2024
  29. MAXWELL S, Okabe J, Kaipananickal H, Rodriguez H, et al
    Set7 Methyltransferase and Phenotypic Switch in Diabetic Glomerular Endothelial Cells.
    J Am Soc Nephrol. 2024 Apr 17. doi: 10.1681/ASN.0000000000000345.
    PubMed     Abstract available


  30. ISAKSSON GL, Hinrichs GR, Andersen H, Bach ML, et al
    Amiloride Reduces Urokinase/Plasminogen-Driven Intratubular Complement Activation in Glomerular Proteinuria.
    J Am Soc Nephrol. 2024;35:410-425.
    PubMed     Abstract available


    January 2024
  31. FWU CW, Eggers PW, Norton JM, Gipson DS, et al
    Age- and Race-Specific Changes in End Stage Kidney Disease Incidence over Four Decades.
    J Am Soc Nephrol. 2024 Jan 30. doi: 10.1681/ASN.0000000000000310.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Diabetes is free of charge.